CN
Search Within
Y0000602
应用筛选条件
关键词:'Y0000602'
显示 1-30 共 251 条结果 关于 "Y0000602" 范围 论文
Michael E Rytting et al.
Cancer, 120(23), 3660-3668 (2014-07-22)
Various trials have reported improved outcomes for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) who received treatment with pediatric-based regimens. Those reports prompted the current investigation of the pediatric augmented Berlin-Frankfurt-Münster (ABFM) regimen in AYA patients. The
Sergej Pirkmajer et al.
Diabetes, 64(2), 360-369 (2014-10-24)
Methotrexate (MTX) is a widely used anticancer and antirheumatic drug that has been postulated to protect against metabolic risk factors associated with type 2 diabetes, although the mechanism remains unknown. MTX inhibits 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/inosine monophosphate cyclohydrolase (ATIC) and thereby
Sivakumar R Rathinam et al.
Ophthalmology, 121(10), 1863-1870 (2014-06-12)
To compare the relative effectiveness of methotrexate and mycophenolate mofetil for noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Multicenter, block-randomized, observer-masked clinical trial. Eighty patients with noninfectious intermediate, posterior, or panuveitis requiring corticosteroid-sparing therapy at Aravind Eye Hospitals in Madurai
Christian A Waimann et al.
Arthritis and rheumatism, 65(6), 1421-1429 (2013-06-04)
To quantify adherence to oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis (RA), using electronic medication monitoring, and to evaluate the clinical consequences of low adherence. A total of 107 patients with RA enrolled in a
Yamei Hu et al.
Toxicology and applied pharmacology, 283(1), 1-8 (2015-01-13)
Liposarcoma is the most common soft tissue sarcoma with a high risk of relapse. Few therapeutic options are available for the aggressive local or metastatic disease. Here, we report that the clinically used proteasome inhibitor bortezomib exhibits significantly stronger cytotoxicity
Jeremy Hugh et al.
Journal of the American Academy of Dermatology, 70(1), 168-177 (2013-11-05)
Many studies have identified cardiovascular risk factors in patients with psoriasis. Some psoriasis therapies may increase cardiovascular disease (CVD) and others may decrease CVD. We reviewed the literature to define the impact of common psoriasis therapies on cardiovascular measures and
A Perez-Delboy et al.
BJOG : an international journal of obstetrics and gynaecology, 121(2), 163-169 (2014-01-01)
Abnromalities of placentation, including placenta accreta, represent a major source of morbidity and mortality among women. Traditional management consists of peripartum hysterectomy at the time of delivery, although more conservative treatments have also been developed recently. In this review we
Phuong Thu Vu Hoang et al.
Journal of pediatric hematology/oncology, 36(7), 534-540 (2013-12-11)
To compare the relapse-free survival (RFS) in Vietnamese (n=141) and white (n=94) children living in Vietnam and Belgium, respectively, and treated in their own country for acute lymphoblastic leukemia according to the same FRALLE 2000 protocol. RFS was significantly worse
Marguerite S Joly et al.
Journal of immunology (Baltimore, Md. : 1950), 193(8), 3947-3958 (2014-09-12)
Biologic drugs, including enzyme-replacement therapies, can elicit anti-drug Abs (ADA) that may interfere with drug efficacy and impact patient safety. In an effort to control ADA, we focused on identifying regimens of immune tolerance induction that may be readily available
Rym Chioukh et al.
Drug metabolism and disposition: the biological fate of chemicals, 42(12), 2041-2048 (2014-09-23)
The coadministration of methotrexate (MTX) and proton pump inhibitors (PPIs) can result in a pharmacokinetic interaction that delays MTX elimination and subsequently increases the MTX blood concentrations. Human organic anion transporters (hOATs) are responsible for the renal tubular secretion of
Nathalie K Zgheib et al.
Pharmacogenetics and genomics, 24(8), 387-396 (2014-07-10)
The aim of this study is to analyze polymorphisms in genes involved in 6-mercaptopurine detoxification (TPMT); methotrexate (MTX) metabolism including ABCB1 (or MDR1), ABCC2, SLC19A1 (or RFC1), and SLCO1B1; and the MTX effect mainly MTHFR and TYMS, and to assess
J Bluett et al.
The Analyst, 140(6), 1981-1987 (2015-02-12)
Rheumatoid arthritis (RA) is a common autoimmune disease that causes significant disability and reduced life expectancy. The folate antagonist methotrexate (MTX) is first-line therapy for RA when used weekly at low doses (5-25 mg). However, the true rate of adherence
O V Kalinina et al.
Patologicheskaia fiziologiia i eksperimental'naia terapiia, (1)(1), 70-74 (2013-06-29)
We studied the role of the natural triterpenoid miliacin (3-3-methoxy-Al8-oleanene) in the regulation of oxidative stress in the liver of (CBAxC57B1(6))F1 mice exposed to methotrexate. Miliacin attenuated methotrexate-induced lipid peroxidation as determined by an attenuation of thiobarbituric acid-reacting products in
Hala O El Mesallamy et al.
Journal of cancer research and clinical oncology, 140(8), 1359-1365 (2014-04-11)
High-dose methotrexate (HD-MTX) is a cornerstone antineoplastic drug in most treatment protocols of pediatric acute lymphoblastic leukemia (ALL). Among the membrane efflux transporters of MTX, the human breast cancer resistant protein is the second member of the G subfamily of
Maika Kissei et al.
Drug metabolism and pharmacokinetics, 29(5), 367-372 (2014-04-04)
Folic acid (FA) is a water-soluble vitamin, and orally ingested FA is absorbed from the small intestine by the proton-coupled folate transporter (PCFT). In the present study, we investigated whether epigallocatechin gallate (EGCG), one of the tea catechins, affects the
Zibin Yang et al.
International journal of clinical pharmacology and therapeutics, 52(5), 346-351 (2014-03-13)
The aim of this study was to evaluate the efficacy of methotrexate (MTX) in the treatment of ankylosing spondylitis (AS). The literature on controlled clinical trials was searched from MEDLINE, EMBASE, OVID, and Cochrane Library databases up to November 2012.
Therapy: oral or subcutaneous methotrexate for rheumatoid arthritis?
Sabri Alsaeedi et al.
Nature reviews. Rheumatology, 10(10), 578-579 (2014-08-06)
Chen Lossos et al.
British journal of haematology, 165(5), 640-648 (2014-02-28)
Primary central nervous system lymphoma (PCNSL) is an aggressive sub-variant of non-Hodgkin lymphoma (NHL) with morphological similarities to diffuse large B-cell lymphoma (DLBCL). While methotrexate (MTX)-based therapies have improved patient survival, the disease remains incurable in most cases and its
Shun-suke Tanaka et al.
PloS one, 9(7), e103439-e103439 (2014-07-26)
The gene amplification plays a critical role in the malignant transformation of mammalian cells. The most widespread method for amplifying a target gene in cell culture is the use of methotrexate (Mtx) treatment to amplify dihydrofolate reductase (Dhfr). Whereas, we
Response to H Zeidler's comments on the CONCERTO study.
Gerd R Burmester et al.
Annals of the rheumatic diseases, 73(8), e51-e51 (2014-06-11)
Koya Fushimi et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 41(4), 449-453 (2014-04-20)
Japanese clinical trials of a tegafur/uracil(UFT)-based postoperative chemotherapy regimen compared with cyclophosphamide, methotrexate, and fluorouracil(CMF)treatment have shown that UFT is not inferior to CMF for the treatment of hormone receptor-positive breast cancer patients. However, the usefulness of UFT for hormone
Lama Azar et al.
Arthritis & rheumatology (Hoboken, N.J.), 66(10), 2862-2870 (2014-06-20)
To evaluate the efficacy and safety of rituximab (RTX) induction therapy and the duration of remission, when RTX is used with or without a conventional maintenance agent, in a cohort of patients with granulomatosis with polyangiitis (Wegener's) (GPA). This was
Mette Levinsen et al.
Cancer chemotherapy and pharmacology, 75(1), 59-66 (2014-10-29)
Through enhancement of 6-mercaptopurine (6MP) bioavailability and inhibition of purine de novo synthesis, high-dose methotrexate (HD-MTX) may increase incorporation into DNA of 6-thioguanine nucleotides, the cytotoxic metabolites of 6MP. Patients with intermediate activity of thiopurine methyltransferase (TPMT(IA)) have higher cytosol
Mai Furumiya et al.
Drug metabolism and pharmacokinetics, 29(4), 312-316 (2014-02-05)
Myricetin is a flavonoid that has recently been suggested to interfere with the intestinal folate transport system. The present study was conducted to examine that possibility, focusing on its inhibitory effect on proton-coupled folate transporter (PCFT) as the molecular entity
[Serious organ damage and intractable clinical conditions in rheumatic and connective tissue disease--progress in pathophysiology and treatment. Topics: II. Clinical conditions special attention needed to be paid to; 4. Macrophage activating syndrome and hemophagocytic syndrome].
Yoshinori Komagata
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 102(10), 2639-2644 (2014-01-10)
Reply of the authors.
Christina E Boots et al.
Fertility and sterility, 101(4), e24-e24 (2014-02-19)
Rongrong Jiang et al.
British journal of pharmacology, 172(4), 1059-1073 (2014-10-10)
Ginsenosides are bioactive saponins derived from Panax notoginseng roots (Sanqi) and ginseng. Here, the molecular mechanisms governing differential pharmacokinetics of 20(S)-protopanaxatriol-type ginsenoside Rg1 , ginsenoside Re and notoginsenoside R1 and 20(S)-protopanaxadiol-type ginsenosides Rb1, Rc and Rd were elucidated. Interactions of
Daisy Puttevils et al.
Acta cardiologica, 69(2), 111-118 (2014-05-03)
Patients with established rheumatoid arthritis (RA) have a higher cardiovascular morbidity and mortality in comparison with the general population. It is considered to be an independent risk factor for cardiovascular disease. The purpose of this article is to describe the
Cutaneous Rosai-Dorfman disease successfully treated with low-dose methotrexate.
Natalie Z Sun et al.
JAMA dermatology, 150(7), 787-788 (2014-05-03)
Kazuhisa Katayama et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 40(5), 655-658 (2013-07-19)
Carcinomatous peritonitis may develop after operation for gastric cancer. As ascites are difficult to control, especially for gastric cancer postoperative carcinomatous peritonitis, many cases are difficult to treat. The present case was a female patient with carcinomatous peritonitis that occurred
1/9